Zomedica announces therapeutic development milestonesDecember 13, 2017Zomedica Pharmaceuticals Corp. veterinary pharmaceutical and diagnostic company announced a development update on the company's four therapeutic candidates for use in companion animals, namely dogs and cats. ZM-012 and ZM-007: Metronidazole for acute diarrhea in dogs Development milestones for ZM-012 and ZM-007, complementary oral formulations of metronidazole targeting the treatment of acute diarrhea in dogs include: Finalized novel tablet formulation for ZM-012 to replace the large, bitter tasting human-approved generic tablet commonly prescribed by veterinarians for their canine patients. The beef-flavored oral tablets are intended for dogs greater than 9 pounds or 4 kilograms. Finalized the oral suspension formulation for ZM-007, which is intended for small breeds and puppies under 9 pounds or 4 kilograms. Completed pilot testing for both formulations at Michigan State University College of Veterinary Medicine to measure metronidazole's effectiveness to treat acute diarrhea in dogs. Scheduled December 2017 pre-submission meeting with the U.S. Food and Drug Administration Center for Veterinary Medicine (FDA-CVM) to present the regulatory strategy and development plan for ZM-012. A safety study will commence for ZM-012 in the first half of 2018 for completion in the second half of 2018. The company also expects to hold a pre-submission …
Education Center - SponsoredWhy Some Dogs Keep Seizing: Understanding and Managing Refractory Epilepsyby • PRN PharmacalThe severe impact of drug-resistant epilepsy highlights the importance of aiming for complete seizure control in all dogs experiencing seizures. It's crucial to enhance our understanding of the reasons behind drug resistance and how they relate to various causes, progression of the disease, and affected breeds.
